Table 1.
Clinicopathological characteristics.
| Variable | Total Sample = 67 | With Primary ET Resistance n = 29 (44%) |
Without Primary ET Resistance n = 38 (56%) |
p-Value | |
|---|---|---|---|---|---|
| n | % | n (%) | n (%) | ||
| Age (year) | |||||
| <35 | 4 | 5.97 | 3 (75) | 1 (25) | 0.187 |
| ≥35 | 63 | 94.03 | 26 (41.27) | 37 (58.73) | |
| ER status | |||||
| Negative (<1%) | 0 | 0 | 0 | 0 | 0.685 |
| 1–20% | 6 | 8.96 | 3 (50) | 3 (50) | |
| 20–50% | 11 | 16.42 | 3 (27.27) | 8 (72.73) | |
| 50–80% | 14 | 20.9 | 6 (42.86) | 8 (57.14) | |
| ≥80 | 36 | 53.73 | 17 (47.22) | 19 (52.78) | |
| Progesterone Receptor Status | |||||
| Positive | 63 | 94.03 | 26 (41.27) | 37 (58.73) | 0.187 |
| Negative | 4 | 5.97 | 3 (75) | 1 (25) | |
| Stage | |||||
| Stage IIIa | 26 | 40 | 14 (53.85) | 12 (46.15) | 0.152 |
| Stage IIIb | 38 | 58.46 | 13 (34.21) | 25 (65.79) | |
| Stage IIIc | 1 | 1.54 | 1 (100) | 0 (0) | |
| Histopathological Grade | |||||
| I | 1 | 1,49 | 0 (0) | 1 (100) | 0.265 |
| II | 29 | 43.28 | 10 (34.48) | 19 (65.52) | |
| III | 37 | 55.22 | 19 (51.35) | 18 (48.65) | |
| Neo-adjuvant chemotherapy | |||||
| Taxane based | 10 | 14.93 | 5 (50) | 5 (50) | 0.061 |
| Doxorubicin based | 47 | 70.15 | 16 (34.04) | 31 (65.96) | |
| Taxan and doxorubicin combination | 6 | 8.96 | 5 (83.33) | 1 (16.67) | |
| Taxan and platinum combination | 4 | 5.97 | 3 (75) | 1 (25) | |
| Radiotherapy | |||||
| Yes | 7 | 10.45 | 4 (57.14) | 3 (42.86) | 0.457 |
| No | 60 | 89.55 | 25 (41.67) | 35 (58.33) | |
| Endocrine Therapy | |||||
| SERM | 26 | 38.81 | 7 (26.92) | 19 (73.08) | 0.296 |
| Aromatase inhibitor | 19 | 28.36 | 10 (52.63) | 9 (47.37) | |
| SERD | 1 | 1.49 | 1 (100) | 0 (0) | |
| SERM, aromatase inhibitor | 5 | 7.46 | 2 (40) | 3 (60) | |
| LHRH/GnRH agonist, SERM | 16 | 22.88 | 9 (56.25) | 7 (43.75) | |
ET: endocrine therapy, SERM: selective estrogen receptor modulator, AI: aromatase inhibitor, SERD: selective estrogen receptor degrader, LHRH: luteinizing hormone-releasing hormone, GnRH: gonadotropin-releasing hormone.